National Multiple Sclerosis Society recommendations for Autologous Hematopoietic Stem Cell Transplant (AHSCT) in Multiple Sclerosis (MS)

Recommendations state the best candidates for AHSCT are likely people with relapsing MS, substantial breakthrough disease despite treatment with disease-modifying therapies, younger than 50 years and with shorter durations of disease (<10 years).

Source:

JAMA Neurology